NCT06649331View on ClinicalTrials.gov

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions
Advanced Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer (TNBC)HER2-negative Breast CancerBreast Cancer
Interventions
DRUG

SHR-A1811

A HER2-directed ADC, via intravenous (into the vein) infusion per protocol.

DRUG

SHR-A1921

A TROP2-directed ADC, via intravenous (into the vein) infusion per protocol.

DRUG

SHR-A2009

A HER3-directed ADC, via intravenous (into the vein) infusion per protocol.

DRUG

SHR-A2102

A Nectin4-directed ADC, via intravenous (into the vein) infusion per protocol.

Trial Locations (1)

200032

RECRUITING

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER